Rituximab Treatment for Posttransplant Lymphoproliferative Disorder (PTLD) Induces Complete Remission of Recurrent Nephrotic Syndrome

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2005 Sep 1

PMID 16133051

Citations 54

Authors

Kandai Nozu

Kazumoto Iijima

Masato Fujisawa

Atsuko Nakagawa

Norishige Yoshikawa

Masafumi Matsuo

Affiliations

Soon will be listed here.

Abstract

A 12-year-old Japanese boy who underwent kidney transplantation with a kidney from his mother developed severe proteinuria immediately after the operation. Because his original disease was nephrotic syndrome (focal segmental glomerulosclerosis, or FSGS) and electron microscopic examination of the renal biopsy showed foot process fusion, we diagnosed this as a recurrence of nephrotic syndrome to the transplanted kidney. Four months after the transplantation, posttransplant lymphoproliferative disorder (PTLD) developed, which was pathologically diagnosed as diffuse large B cell lymphoma. Treatment consisting of a reduction in immunosuppression resulted in improvement in PTLD a month after the start of treatment. However, relapse occurred 2 months after the first onset of PTLD, which we treated with rituximab (CD-20 monoclonal antibody 375 mg/m2) once weekly for a total of four doses. The PTLD resolved immediately after the rituximab treatment was started, and, interestingly, urinary protein levels also improved at the same time. Three years later, the boy shows no signs of PTLD, and no proteinuria has been detected. These findings suggest that rituximab may be an effective treatment for recurrence of nephrotic syndrome after transplantation and that activated B cells may play a pivotal role in the recurrence of nephrosis after renal transplantation.

Citing Articles

Review of plasma exchange and rituximab for prevention of recurrent focal segmental glomerulosclerosis after a prior graft loss.

Gharaei S, Abbas H, Kanigicherla D World J Transplant. 2024; 14(4):98155.

PMID: 39697454 PMC: 11438932. DOI: 10.5500/wjt.v14.i4.98155.

Clinical characteristics and favorable treatment responses of recurrent focal segmental glomerulosclerosis or steroid-resistant nephrotic syndrome in children after kidney transplantation.

Dharnidharka V, Scobell R, Kallash M, Davies A, Marchesani N, Maltenfort M Pediatr Nephrol. 2024; 39(11):3317-3331.

PMID: 39001911 PMC: 11662369. DOI: 10.1007/s00467-024-06452-z.

Biologics in steroid resistant nephrotic syndrome in childhood: review and new hypothesis-driven treatment.

Angeletti A, Bruschi M, Kajana X, La Porta E, Spinelli S, Caridi G Front Immunol. 2023; 14:1213203.

PMID: 37705972 PMC: 10497215. DOI: 10.3389/fimmu.2023.1213203.

UK experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant.

Reynolds B, Lamb A, Jones C, Yadav P, Tyerman K, Geddes C Pediatr Nephrol. 2021; 37(1):199-207.

PMID: 34383125 PMC: 8674165. DOI: 10.1007/s00467-021-05248-9.

Immune-mediated entities of (primary) focal segmental glomerulosclerosis.

Braun F, Homeyer I, Alachkar N, Huber T Cell Tissue Res. 2021; 385(2):423-434.

PMID: 33907872 PMC: 8523460. DOI: 10.1007/s00441-021-03454-3.

References

Tejani A, Stablein D . Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol. 1992; 2(12 Suppl):S258-63. DOI: 10.1681/ASN.V212s258. View

Sfikakis P, Boletis J, Lionaki S, Vigklis V, Fragiadaki K, Iniotaki A . Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005; 52(2):501-13. DOI: 10.1002/art.20858. View

Artero M, Biava C, Amend W, Tomlanovich S, Vincenti F . Recurrent focal glomerulosclerosis: natural history and response to therapy. Am J Med. 1992; 92(4):375-83. DOI: 10.1016/0002-9343(92)90267-f. View

Benz K, Dotsch J, Rascher W, Stachel D . Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004; 19(7):794-7. DOI: 10.1007/s00467-004-1434-z. View

Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours J . Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol. 1998; 9(9):1709-15. DOI: 10.1681/ASN.V991709. View

Esnault V, Besnier D, Testa A, Coville P, Simon P, Subra J . Effect of protein A immunoadsorption in nephrotic syndrome of various etiologies. J Am Soc Nephrol. 1999; 10(9):2014-7. DOI: 10.1681/ASN.V1092014. View

Srivastava R, Kalia A, Travis L, Diven S, Gugliuzza K, Rajaraman S . Prompt remission of post-renal transplant nephrotic syndrome with high-dose cyclosporine. Pediatr Nephrol. 1994; 8(1):94-5. DOI: 10.1007/BF00868281. View

Paya C, Fung J, Nalesnik M, Kieff E, Green M, Gores G . Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999; 68(10):1517-25. DOI: 10.1097/00007890-199911270-00015. View

Kemper M, Meyer-Jark T, Lilova M, Muller-Wiefel D . Combined T- and B-cell activation in childhood steroid-sensitive nephrotic syndrome. Clin Nephrol. 2003; 60(4):242-7. DOI: 10.5414/cnp60242. View

10.

Pinkerton C, Hann I, Weston C, Mapp T, Wotherspoon A, Hobson R . Immunodeficiency-related lymphoproliferative disorders: prospective data from the United Kingdom Children's Cancer Study Group Registry. Br J Haematol. 2002; 118(2):456-61. DOI: 10.1046/j.1365-2141.2002.03681.x. View

11.

Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C . Rituximab in idiopathic membranous nephropathy: a one-year prospective study. J Am Soc Nephrol. 2003; 14(7):1851-7. DOI: 10.1097/01.asn.0000071511.35221.b3. View

12.

Tsai D, Hardy C, Tomaszewski J, Kotloff R, Oltoff K, Somer B . Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001; 71(8):1076-88. DOI: 10.1097/00007890-200104270-00012. View

13.

Cook R, Connors J, Gascoyne R, Fradet G, Levy R . Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 1999; 354(9191):1698-9. DOI: 10.1016/S0140-6736(99)02058-9. View

14.

Kakumitsu H, Higuchi M, Tanaka K, Shibuya T . Nephrotic syndrome in a patient with intravascular lymphomatosis. Intern Med. 2003; 42(1):98-101. DOI: 10.2169/internalmedicine.42.98. View

15.

McGhee W, Mazariegos G, Sindhi R, Abu-Elmagd K, Reyes J . Rituximab in the treatment of pediatric small bowel transplant patients with posttransplant lymphoproliferative disorder unresponsive to standard treatment. Transplant Proc. 2002; 34(3):955-6. DOI: 10.1016/s0041-1345(02)02714-8. View

16.

. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.2.5. Chronic graft dysfunction. Late recurrence of primary glomerulonephritides. Nephrol Dial Transplant. 2002; 17 Suppl 4:16-8. View

17.

Savin V, Sharma R, Sharma M, McCarthy E, Swan S, Ellis E . Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996; 334(14):878-83. DOI: 10.1056/NEJM199604043341402. View

18.

Faye A, Quartier P, Reguerre Y, Lutz P, Carret A, Dehee A . Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol. 2001; 115(1):112-8. DOI: 10.1046/j.1365-2141.2001.03041.x. View

19.

Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M . A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991; 40(3):453-60. DOI: 10.1038/ki.1991.232. View

20.

Oertel S, Anagnostopoulos I, Bechstein W, Liehr H, Riess H . Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid.... Transplantation. 2000; 69(3):430-2. DOI: 10.1097/00007890-200002150-00021. View